Orchard Therapeutics plc American Depositary Shares
ORTX
ORTX was delisted on the 23rd of January, 2024.
47 hedge funds and large institutions have $122M invested in Orchard Therapeutics plc American Depositary Shares in 2023 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 11 closing their positions.
160% more capital invested
Capital invested by funds: $46.9M → $122M (+$75.1M)
145% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 11
47% more funds holding
Funds holding: 32 → 47 (+15)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
99% less call options, than puts
Call options by funds: $26K | Put options by funds: $2.07M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$25.2M |
| 2 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$24.6M |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
+$5.23M |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$4.72M |
| 5 |
Millennium Management
New York
|
+$3.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$2.44M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$1.92M |
| 3 |
Mariner
Overland Park,
Kansas
|
-$1.49M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$936K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$739K |
ORTX Hedge Fund Activity: Q4 2023 in Review
47 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q4 2023, worth a combined $122M — up 160% from $46.9M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ORTX positions and 11 closed out — a net gain of 16 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Blue Owl Capital Holdings, opening a new position worth an estimated $25.2M. The largest seller was Deerfield Management, exiting entirely with an estimated $2.44M sold.
- 47 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q4 2023, up from 32 in Q3 2023.
- Funds reported $122M of Orchard Therapeutics plc American Depositary Shares stock for Q4 2023, up 160% quarter-over-quarter.
- 27 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q4 2023 and 11 closed out, a net change of +16 holders.
- The largest Orchard Therapeutics plc American Depositary Shares buyer in Q4 2023 was Blue Owl Capital Holdings, an estimated $25.2M added.
- The largest Orchard Therapeutics plc American Depositary Shares seller in Q4 2023 was Deerfield Management, an estimated $2.44M sold.
Based on aggregated 13F filings for Q4 2023.